RedHill Biopharma (RDHL) Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to RedHill Biopharma (RDHL) Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19

RedHill Biopharma (RDHL) Tops Q1 EPS by 29c, Revenues Miss

May 27, 2021 7:03 AM EDT

RedHill Biopharma (NASDAQ: RDHL) reported Q1 EPS of ($0.05), $0.29 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $22.7 million.

Dror Ben-Asher, RedHill's Chief Executive Officer, said: "The progress of our two novel, oral COVID-19 programs has put RedHill at the forefront of oral COVID-19... More